2007
Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners
Springer SA, Friedland GH, Doros G, Pesanti E, Altice FL. Antiretroviral Treatment Regimen Outcomes Among HIV-Infected Prisoners. HIV Research & Clinical Practice 2007, 8: 205-212. PMID: 17720660, PMCID: PMC2409059, DOI: 10.1310/hct0804-205.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyImmunological outcomesHIV-1 RNA levelsCells/mulActive antiretroviral therapyEffective antiretroviral therapyRetrospective cohort studyDuration of therapyKaplan-Meier curvesHIV-1 RNAProportion of subjectsHAART strategyTriple NRTICohort studyCopies/Incarceration periodsTreatment strategiesHigh prevalenceMean changeStudy groupNRTIsHIVTherapyRNA levelsLaboratory data
2006
Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
McCance-Katz EF, Moody DE, Smith PF, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir. Clinical Infectious Diseases 2006, 43: s235-s246. PMID: 17109310, DOI: 10.1086/508188.Peer-Reviewed Original ResearchMeSH KeywordsAdultBuprenorphineCase-Control StudiesCohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV Protease InhibitorsHIV SeronegativityHumansLopinavirMaleNarcotic AntagonistsNelfinavirOpioid-Related DisordersProbabilityPyrimidinonesReference ValuesRisk AssessmentRitonavirConceptsLPV/rLopinavir/ritonavirProtease inhibitor nelfinavirOpioid dependenceAdministration of ritonavirOpioid partial agonistAdjustment of dosesHuman immunodeficiency virusConcentration-time curveHealthy control participantsPI administrationPI pharmacokineticsHIV diseaseNegative volunteersImmunodeficiency virusOpiate withdrawalDrug interactionsBuprenorphineRitonavirPartial agonistNelfinavirControl participantsPharmacokinetic studyAdministrationSignificant increaseInteractions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey PM. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006, 43: s224-s234. PMID: 17109309, DOI: 10.1086/508187.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesArea Under CurveBenzoxazinesBuprenorphineCase-Control StudiesCohort StudiesCyclopropanesDelavirdineDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHIV InfectionsHumansMaleNarcotic AntagonistsOpioid-Related DisordersOxazinesProbabilityPrognosisReference ValuesReverse Transcriptase InhibitorsRisk AssessmentStatistics, NonparametricTreatment OutcomeConceptsNonnucleoside reverse transcriptase inhibitor efavirenzReverse transcriptase inhibitor efavirenzInhibitor efavirenzPharmacokinetics of buprenorphineOpiate withdrawal symptomsAdjustment of dosesEffects of buprenorphineHuman immunodeficiency virusConcentration-time curveOpioid-dependent participantsHealthy control participantsAntiretroviral administrationAdverse eventsAgonist medicationsHIV diseaseNegative volunteersStandard dosesOpioid dependenceImmunodeficiency virusBuprenorphine concentrationsWithdrawal symptomsAntiretroviral pharmacokineticsDrug interactionsOpiate dependenceBuprenorphine
1994
Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users
Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Annals Of Epidemiology 1994, 4: 17-26. PMID: 7911376, DOI: 10.1016/1047-2797(94)90038-8.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBaltimoreCD4-Positive T-LymphocytesCohort StudiesConfidence IntervalsHIV InfectionsHIV SeroprevalenceHomosexualityHumansIncidenceLeukocyte CountLife TablesMaleModels, StatisticalNew York CityPlatelet CountRegression AnalysisSubstance Abuse, IntravenousSurvival RateTime FactorsConceptsHIV infectionDrug usersImmunodeficiency syndromeMedian timeCombined cohortHomosexual menHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus (HIV) epidemicPercent of CD4Immunodeficiency virus infectionIncident HIV infectionProduct-limit methodMarkers of maturityHIV incubation distributionsPlatelet countVirus infectionLarge cohortSeroconversionCohortInfectionConfidence intervalsIncubation distributionAIDSVirus epidemicPopulation groupsLaboratory markers and the risk of developing HIV-1 disease among injecting drug users
Alcabes P, Selwyn P, Davenny K, Hartel D, Buono D, Schoenbaum E, Klein R, Friedland G. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. AIDS 1994, 8: 107-116. PMID: 7912083, DOI: 10.1097/00002030-199401000-00016.Peer-Reviewed Original ResearchConceptsCD4 lymphocyte countHIV-1-related outcomesLow CD4 lymphocyte countCD4 lymphocyte numbersPyogenic bacterial infectionsHIV-1 diseaseLymphocyte countLaboratory markersLymphocyte numbersClinical eventsAIDS diagnosisRelative riskDrug usersBacterial infectionsHIV-1-associated diseaseBeta 2M levelsSerum beta 2M levelsDifferent laboratory markersMultiple constitutional symptomsAIDS riskMethadone treatment programsPredictors of progressionHIV-1 infectionLow platelet countLower leukocyte counts
1993
Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users.
Gourevitch M, Selwyn P, Davenny K, Buono D, Schoenbaum E, Klein R, Friedland G. Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Annals Of Internal Medicine 1993, 118: 350-5. PMID: 8094280, DOI: 10.7326/0003-4819-118-5-199303010-00005.Peer-Reviewed Original ResearchConceptsIntravenous drug usersTreatment of syphilisStages of syphilisSerologic manifestationsDrug usersNontreponemal titersHIV infectionHuman immunodeficiency virus (HIV) infectionMethadone maintenance treatment programHIV serologic statusHIV-seronegative patientsHIV-seropositive patientsImmunodeficiency virus infectionHIV seropositive casesMaintenance treatment programFulminant manifestationCD4 countCohort studyHIV-seropositiveClinical courseStandard dosesEarly syphilisClinical manifestationsSerologic statusSerologic testsIncubation Period of Human Immunodeficiency Virus
Alcabes P, Muñoz A, Vlahov D, Friedland G. Incubation Period of Human Immunodeficiency Virus. Epidemiologic Reviews 1993, 15: 303-318. PMID: 8174659, DOI: 10.1093/oxfordjournals.epirev.a036122.Peer-Reviewed Original Research
1991
Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection?
Khabbaz R, Hartel D, Lairmore M, Horsburgh C, Schoenbaum E, Roberts B, Hartley T, Friedland G. Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection? The Journal Of Infectious Diseases 1991, 163: 252-256. PMID: 1988509, DOI: 10.1093/infdis/163.2.252.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman T-lymphotropic virus type II (HTLV-II) infectionHTLV-II infectionType II infectionPolymerase chain reactionRisk factorsHTLV-IIDrug usersHuman immunodeficiency virus (HIV) infectionHIV infection statusImmunodeficiency virus infectionIntravenous drug useMethadone maintenance programTransfusion historyNeedle sharingVirus infectionSerologic resultsSex partnersDrug useShooting galleriesEndemic infectionInfectionOlder ageInfection statusOld infection